Recent Blog Articles
Not yet ready for cataract surgery? Try these tips
Back to the future: Psychedelic drugs in psychiatry
Children not yet vaccinated against COVID-19? What to do
HIV rates rising: Could new forms of PrEP help?
Careful! Scary health news can be harmful to your health
Post-pandemic weight loss: There’s an app for that
Cognitive behavioral therapy for insomnia by telemedicine: Is it as good as in-person treatment?
Prediabetes diagnosis as an older adult: What does it really mean?
Is blood sugar monitoring without diabetes worthwhile?
Large review study finds low risk of erectile dysfunction after prostate biopsy
Gad Marshall, MD
Gad Marshall, MD, is board certified in Neurology. He is currently the Associate Medical Director of Clinical Trials at the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital; Associate Neurologist at Brigham and Women’s Hospital; Assistant in Neurology at Massachusetts General Hospital; and Assistant Professor of Neurology at Harvard Medical School. Dr. Marshall has been site principal investigator for multiple clinical trials of amyloid-modifying drugs in Alzheimer’s disease and is currently the site principal investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 3, DoD-ADNI, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial. His research has focused on clinical correlates of activities of daily living and neuropsychiatric symptoms with multiple imaging markers and cerebrospinal fluid biomarkers across the early Alzheimer’s disease spectrum, as well as developing novel, sensitive, and ecologically-valid assessments for early functional changes in Alzheimer’s disease.